buserelin
Sponsors
Novartis Pharma AG, NCIC Clinical Trials Group, Yazd Research & Clinical Center for Infertility, Yazd Medical University, Andros Day Surgery Clinic
Conditions
In Vitro FertilizationOvarian StimulationPSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)PregnancyProstate AdenocarcinomaProstate CancerStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8
Phase 1
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
CompletedNCT00054106
Start: 2002-12-10End: 2008-09-22Updated: 2023-08-04
Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification
NCT00823121
Start: 2008-08-31End: 2009-12-31Target: 500Updated: 2010-01-20
Phase 3
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
CompletedNCT00002633
Start: 1995-02-08End: 2012-01-06Updated: 2020-04-03
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
CompletedNCT00003653
Start: 1999-01-05End: 2013-01-10Updated: 2021-06-23
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
TerminatedNCT00651326
Start: 2008-06-02End: 2011-01-18Updated: 2023-08-04
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Active, not recruitingNCT04513717
Start: 2021-01-21End: 2033-12-31Updated: 2026-04-03
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
RecruitingNCT05050084
Start: 2021-12-06End: 2026-11-11Target: 2050Updated: 2026-01-14
PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Active, not recruitingCTIS2023-507970-42-00
Start: 2021-03-31Target: 445Updated: 2026-01-26
Phase 4
Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist
CompletedNCT00830492
Start: 2008-01-31End: 2008-12-31Target: 200Updated: 2009-01-28
Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor Responders
CompletedNCT01213147
Start: 2009-04-30End: 2010-05-31Updated: 2010-10-01
Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles
TerminatedNCT01816789
Start: 2013-03-31End: 2016-07-31Updated: 2016-12-23